- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Anthem Biosciences Limited — Updates, 05-02-2026: Press Release (Revised)
05-02-2026 | 02:06 pm
05-02-2026 | 02:06 pm
Anthem Biosciences reported strong 9MFY26 results: Revenue ₹1,513.4 Cr, EBITDA ₹671.2 Cr (41.5% margin), PAT ₹402.0 Cr. Q3 revenue saw a decline, but resilient 41.8% EBITDA margins boosted profitability. An exceptional ₹25.4 Cr charge was booked. Management anticipates a robust FY26 finish.
No comments yet. Be the first to comment!